Edition:
United States

Arbutus Biopharma Corp (ABUS.OQ)

ABUS.OQ on NASDAQ Stock Exchange Global Select Market

6.00USD
23 May 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$6.00
Open
$6.00
Day's High
$6.00
Day's Low
$6.00
Volume
677
Avg. Vol
36,821
52-wk High
$8.25
52-wk Low
$3.20

Latest Key Developments (Source: Significant Developments)

Arbutus Announces Corporate Update
Wednesday, 14 Mar 2018 04:00pm EDT 

March 14 (Reuters) - Arbutus Biopharma Corp ::ARBUTUS ANNOUNCES CORPORATE UPDATE AND YEAR-END 2017 FINANCIAL RESULTS.ARBUTUS BIOPHARMA CORP - ‍ARB-1467 PHASE II COMBINATION STUDY BEGINNING IN 1Q18​.ARBUTUS BIOPHARMA CORP - ‍INTERIM ON-TREATMENT RESULTS FROM ARB-1467 STUDY ARE EXPECTED IN SECOND HALF OF 2018, FOLLOWED BY FINAL RESULTS IN 2019 ​.ARBUTUS BIOPHARMA CORP - ‍AB-452 TO ENTER CLINICAL DEVELOPMENT​.  Full Article

Arbutus Settles Litigation Terminating Acuitas Rights To LNP Technology
Thursday, 22 Feb 2018 04:35pm EST 

Feb 22 (Reuters) - Arbutus Biopharma Corp ::ARBUTUS SETTLES LITIGATION, TERMINATING ACUITAS’ RIGHTS TO LNP TECHNOLOGY.ARBUTUS BIOPHARMA CORP - ‍SETTLEMENT TERMINATES ACUITAS' RIGHT TO USE OR SUBLICENSE OUR LNP TECHNOLOGY GOING FORWARD​.ARBUTUS BIOPHARMA - ‍SETTLEMENT STIPULATES THAT 4 NON-EXCLUSIVE VIRAL VACCINE SUBLICENSES PREVIOUSLY GRANTED TO MODERNA ARE ONLY SUBLICENSES TO SURVIVE​.ARBUTUS BIOPHARMA - LITIGATION INITIATED BY ACUITAS THERAPEUTICS ON OCT. 25, 2016 IN SUPREME COURT OF BRITISH COLUMBIA HAS BEEN SETTLED BEFORE TRIAL​.  Full Article

Arbutus Announces Departure Of CFO Bruce Cousins
Tuesday, 13 Feb 2018 09:36pm EST 

Feb 13 (Reuters) - Arbutus Biopharma Corp ::ARBUTUS ANNOUNCES DEPARTURE OF CHIEF FINANCIAL OFFICER; APPOINTS INTERIM CFO.BRUCE COUSINS, EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER, IS LEAVING CO BUT WILL REMAIN AVAILABLE ON A CONSULTING BASIS.‍KOERT VANDENENDEN, ARBUTUS' VICE PRESIDENT OF FINANCE, WILL SERVE AS INTERIM CHIEF FINANCIAL OFFICER​.‍COMPANY WILL PROMPTLY BEGIN A SEARCH FOR A PERMANENT CHIEF FINANCIAL OFFICER.​.  Full Article

Arbutus Consolidates HBV Business Around Warminster, PA Site
Thursday, 8 Feb 2018 08:30am EST 

Feb 8 (Reuters) - Arbutus Biopharma Corp ::ARBUTUS BIOPHARMA CORP - SITE CONSOLIDATION AND ORGANIZATIONAL RESTRUCTURING TO BETTER ALIGN ITS HBV BUSINESS IN WARMINSTER, PA.ARBUTUS BIOPHARMA CORP - TO ACHIEVE ALIGNMENT, CO WILL REDUCE ITS GLOBAL WORKFORCE BY ABOUT 31 PERCENT AND PLANS TO CLOSE ITS BURNABY FACILITY.ARBUTUS BIOPHARMA CORP - WILL INCUR RESTRUCTURING COSTS RELATED TO WORKFORCE REDUCTION AND SITE CLOSURE OF ABOUT $5.0 MILLION.ARBUTUS BIOPHARMA CORP - ‍RESTRUCTURING COSTS WILL BE PRIMARILY PAID IN CASH IN Q2 OF 2018​.  Full Article

Arbutus’ LNP licensee Alnylam initiates rolling submission of NDA for Patisiran
Thursday, 16 Nov 2017 01:39pm EST 

Nov 16 (Reuters) - Arbutus Biopharma Corp ::Arbutus’ LNP licensee Alnylam initiates rolling submission of New Drug Application (NDA) to U.S. Food and drug Administration (fda) for Patisiran.Says Alnylam expects to submit final clinical data for Patisiran by year end ​.  Full Article

Arbutus Biopharma reports Q3 loss per share $0.21
Thursday, 2 Nov 2017 04:00pm EDT 

Nov 2 (Reuters) - Arbutus Biopharma Corp :Arbutus Biopharma Corp announces corporate update and third quarter 2017 financial results.Q3 non-GAAP loss per share $0.17.Q3 loss per share $0.21.Q3 earnings per share view $-0.37 -- Thomson Reuters I/B/E/S.  Full Article

Gritstone Oncology and Arbutus Biopharma announce LNP technology licensing agreement
Wednesday, 18 Oct 2017 08:00am EDT 

Oct 18 (Reuters) - Arbutus Biopharma Corp : :Gritstone Oncology and Arbutus Biopharma announce LNP technology licensing agreement to develop novel RNA-based personalized neoantigen immunotherapies for cancer patients.Arbutus Biopharma Corp - is deploying proprietary lipid nanoparticle technology to deliver gritstone's rna-based neoantigen immunotherapy products​.Arbutus Biopharma - ‍under terms of license agreement, gritstone obtains worldwide access to arbutus' portfolio of proprietary and LNP products​.Arbutus Biopharma - ‍Gritstone will pay co upfront payment, payments for achievement of development, regulatory, and commercial milestones.  Full Article

Arbutus to Receive $116 Million Strategic Investment from Roivant Sciences
Monday, 2 Oct 2017 07:00am EDT 

Oct 2 (Reuters) - Arbutus Biopharma Corp ::Signed share purchase agreement with Roivant Sciences for sale of convertible preferred shares for $116.4 million.Intends to use proceeds from sale to further develop, advance its clinical, preclinical HBV pipeline programs.Roivant will invest preferred shares which will be convertible into common shares at conversion price of $7.13/share.Roivant has agreed to a four year lock‐up period for the preferred shares investment and its existing holdings in co.  Full Article

Arbutus announces topline results for ARB-1467 phase II Cohort 4
Monday, 25 Sep 2017 08:00am EDT 

Sept 25 (Reuters) - Arbutus Biopharma Corp ::Arbutus Biopharma Corp announces topline results for ARB-1467 phase ii cohort 4.Arbutus Biopharma Corp - seven of the twelve patients met the predefined response criteria at or before day 71.Arbutus -initial results for monthly dosing extension suggest monthly dosing not sufficient to maintain/improve on reductions in s-antigen levels.Arbutus Biopharma - detailed results of cohort 4 are expected to be presented at AASLD in October.Arbutus Biopharma - planning to initiate new study of ARB-1467 in Q4 to evaluate longer dosing of ARB-1467 combined with Interferon.Arbutus Biopharma Corp - all 12 patients in cohort 4 experienced reductions in serum HBsAg levels.Arbutus Biopharma - to initiate new study in Q4 to study longer term Bi-weekly dosing of ARB-1467 in combination with Tenofovir.  Full Article

Arbutus Biopharma Q2 loss per share $0.33
Thursday, 3 Aug 2017 04:00pm EDT 

Aug 3 (Reuters) - Arbutus Biopharma Corp :Arbutus announces corporate update and second quarter 2017 financial results.Q2 non-gaap loss per share $0.28.Q2 loss per share $0.33.Q2 earnings per share view $-0.42 -- Thomson Reuters I/B/E/S.Q2 revenue $1.0 million versus $300,000.Q2 revenue view $592,000 -- Thomson Reuters I/B/E/S.Arbutus Biopharma - ‍as at June 30, 2017, arbutus had cash, cash equivalents, short-term investments and restricted investments totaling $115.6 million.  Full Article

BRIEF-Arbutus Announces Corporate Update

* ARBUTUS ANNOUNCES CORPORATE UPDATE AND YEAR-END 2017 FINANCIAL RESULTS